January 5, 2017
Valneva, Merck in new animal vaccines deal (U.S.&Canada)
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
Pharmaceuticals, Biotechnology and Life Sciences
Valneva has given Merck in United States and Canada rights to use its EB66 technology to research new veterinary vaccines.
French vaccines developer Valneva has closed the share issuance in connection with MVM Life Science Partners LLP`s investment in the…
Valneva said on Friday it will sent its Lyme disease vaccine candidate VLA15 to clinic. Phase I testing can begin…
Valneva has reported financial results for first nine months of 2016.
GE Healthcare and Valneva have joined forces to create cell culture medium for vaccine
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target